South Carolina Patent of the Month – October 2024
Integrated Micro-Chromatography Systems (IMCS) has pioneered a transformative innovation in enzyme engineering with their enhanced variant of the **Pseudomonas aeruginosa sulfatase (PaS)** enzyme. This groundbreaking advancement addresses a critical need in clinical, forensic, and environmental testing by offering a superior solution for the hydrolysis of sulfated drug metabolites—targets that have long posed challenges for conventional detection methods.
The novel PaS variants developed by IMCS incorporate strategic amino acid substitutions, particularly at position A139, coupled with additional modifications at key residues. These enhancements result in a sulfatase with significantly elevated activity, broader substrate specificity, and higher precision in metabolite processing. Unlike traditional enzyme preparations, these recombinant PaS enzymes can be produced in highly purified forms, eliminating contaminants that often complicate analysis.
This invention is particularly impactful in **urine drug testing (UDT)**, where sulfated metabolites of substances like steroids and β-agonists are prevalent. Current approaches, including chemical hydrolysis and traditional enzyme treatments, frequently struggle with target degradation and inconsistent results. IMCS’s engineered PaS variants overcome these limitations, enabling faster, more reliable deconjugation of sulfated metabolites under milder conditions. This advancement not only enhances testing throughput but also ensures the accuracy and reproducibility critical for high-stakes applications, such as anti-doping protocols and neonatal drug exposure assessments.
Beyond clinical and forensic contexts, these PaS variants hold promise in **environmental testing** and **nutritional studies**, where deconjugation of sulfated contaminants or dietary metabolites is essential. By expanding the enzyme toolkit available for these fields, IMCS reaffirms its commitment to driving innovation in analytical biochemistry, delivering solutions that streamline workflows, improve outcomes, and empower researchers worldwide.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
